Search results for "Anemia"

showing 10 items of 352 documents

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the firs…

2016

BACKGROUND: Standard treatment for patients with primary CNS lymphoma remains to be defined. Active therapies are often associated with increased risk of haematological or neurological toxicity. In this trial, we addressed the tolerability and efficacy of adding rituximab with or without thiotepa to methotrexate-cytarabine combination therapy (the MATRix regimen), followed by a second randomisation comparing consolidation with whole-brain radiotherapy or autologous stem cell transplantation in patients with primary CNS lymphoma. We report the results of the first randomisation in this Article.METHODS: For the international randomised phase 2 International Extranodal Lymphoma Study Group-32 …

MaleComparative Effectiveness ResearchTransplantation ConditioningGastrointestinal DiseasesDenmarkMedizinKaplan-Meier EstimateDexamethasoneCentral Nervous System NeoplasmsDeath Sudden0302 clinical medicineIntraocular LymphomaGermanyAntineoplastic Combined Chemotherapy ProtocolsMedicineStandard treatmentOptic Nerve NeoplasmsPoisoningRemission InductionCytarabineHematopoietic Stem Cell TransplantationAnemiaHematologyInduction ChemotherapyAcute Kidney InjuryMiddle AgedCombined Modality TherapyMagnetic Resonance Imaging3. Good healthStrokeTreatment OutcomeTolerabilityItaly030220 oncology & carcinogenesischemoimmunotherapyRituximabFemaleNeurotoxicity SyndromesChemical and Drug Induced Liver InjuryRituximabSwitzerlandmedicine.drugMucositismedicine.medical_specialtyLymphoma B-CellNeutropeniaThioTEPAInfectionsTransplantation AutologousDisease-Free Survival03 medical and health sciencesprimary CNS lymphomaChemoimmunotherapyInternal medicineJournal Articleprimary CNS lymphoma chemoimmunotherapyHumansbusiness.industryThrombosismedicine.diseaseThrombocytopeniaUnited KingdomSurgeryTransplantationRegimenMethotrexateHeart InjuriesHyperglycemiaRadiotherapy Adjuvantbusiness030217 neurology & neurosurgeryFebrile neutropeniaThiotepaFollow-Up StudiesThe Lancet. Haematology
researchProduct

Bone marrow cell transcripts from Fanconi anaemia patients revealin vivoalterations in mitochondrial, redox and DNA repair pathways

2013

Fanconi anaemia (FA) is a genetic cancer predisposition disorder associated with cytogenetic instability, bone marrow failure and a pleiotropic cellular phenotype, including low thresholds of responses to oxidative stress, cross-linking agents and selected cytokines. This study was aimed at defining the scope of abnormalities in gene expression using the publicly available FA Transcriptome Consortium (FTC) database (Gene Expression Omnibus, 2009 and publicly available as GSE16334). We evaluated the data set that included transcriptomal analyses on RNA obtained from low-density bone marrow cells (BMC) from 20 patients with FA and 11 healthy volunteers, by seeking to identify changes in expre…

MaleDNA Repairiron-chelating proteinsTranscriptome0302 clinical medicineFanconi anemiaGene expressioncytokineoxidative stressChildbioenergetic pathwayRegulation of gene expression0303 health sciencesHematologyGeneral Medicineheat-shock proteinMitochondria3. Good health030220 oncology & carcinogenesisFemaleFanconi anaemiaOxidation-ReductionSignal TransductionAdultiron-chelating proteinDNA repairDNA repairBone Marrow CellsBiologyProinflammatory cytokine03 medical and health sciencesmedicineHumanstranscriptsGene030304 developmental biologyoxidative streGene Expression Profilingheat-shock proteinsMolecular Sequence Annotationmedicine.diseaseMolecular biologycytokinesDNA repair Fanconi anaemia bioenergetic pathways cytokines heat-shock proteins iron-chelating proteins oxidative stress transcriptsGene expression profilingOxidative StressFanconi AnemiaCase-Control Studiesbioenergetic pathwaysTranscriptomeEuropean Journal of Haematology
researchProduct

Autologous peripheral blood stem and progenitor (CD34+) cell transplantation for systemic lupus erythematosus complicated by Evans syndrome.

1998

Immunoablation followed by allogeneic stem cell (SC) transplantation has been shown to be capable of curing a large spectrum of experimental autoimmune disorders, hereditary and/or induced. Superimposable results, albeit with some exceptions, have been obtained in human patients affected by coincidental autoimmune and blood diseases. However, both because of encouraging experimental results and of the procedure's greater safety, autologous SC are being increasingly utilized worldwide. Case reports are being collected in the registry of the European Group for Blood and Marrow Transplantation (EBMT)/European League against Rheumatism (EULAR) Autoimmune Disease Stem Cell Project. Among the se…

MaleEvans syndromeAdolescentmedicine.medical_treatmentAntigens CD34Hematopoietic stem cell transplantation030204 cardiovascular system & hematologyTransplantation Autologous03 medical and health sciences0302 clinical medicineRheumatologyPrednisoneMedicineAutologous transplantationHumansLupus Erythematosus Systemicskin and connective tissue diseases030203 arthritis & rheumatologyLupus anticoagulantPurpura Thrombocytopenic IdiopathicLupus erythematosusbusiness.industryHematopoietic Stem Cell TransplantationSyndromemedicine.diseaseTransplantationImmunologyFemaleAnemia Hemolytic AutoimmunebusinessAnti-SSA/Ro autoantibodiesmedicine.drugLupus
researchProduct

Relationship between lead absorption and iron status and its association with oxidative stress markers in lead-exposed workers

2021

Background: The emission of lead (Pb) occurring during the extraction, processing and industrial applications of this element remains a significant environmental risk factor. The absorbability of lead in humans is strongly associated with the general health status of exposed individuals. Existing mineral deficiencies are considered being a predisposition to an increased Pb uptake. Both, iron deficiency and lead poisoning are the major caus-ative factors responsible for the prevalence of anemia within the vulnerable population, especially in children. Although some of the intervention programs of counteracting lead poisoning by iron supplementation proved to be effective in the Pb-exposed po…

MaleExposed PopulationAnemiaIronPopulationPhysiologymedicine.disease_causeBiochemistryAntioxidantsLead poisoningInorganic ChemistryLead exposurechemistry.chemical_compoundmedicineHumansChildeducationeducation.field_of_studymedicine.diagnostic_testbusiness.industryIron statusZinc protoporphyrinROSIron DeficienciesIron deficiencymedicine.diseaseLead PoisoningOxidative StressBlood leadLeadchemistrySerum ironMolecular MedicinebusinessBiomarkersOxidative stressJournal of Trace Elements in Medicine and Biology
researchProduct

Optimization of anemia treatment in hemodialysis patients via reinforcement learning

2013

Objective: Anemia is a frequent comorbidity in hemodialysis patients that can be successfully treated by administering erythropoiesis-stimulating agents (ESAs). ESAs dosing is currently based on clinical protocols that often do not account for the high inter- and intra-individual variability in the patient's response. As a result, the hemoglobin level of some patients oscillates around the target range, which is associated with multiple risks and side-effects. This work proposes a methodology based on reinforcement learning (RL) to optimize ESA therapy. Methods: RL is a data-driven approach for solving sequential decision-making problems that are formulated as Markov decision processes (MDP…

MaleFOS: Computer and information sciencesMathematical optimizationDarbepoetin alfaComputer scienceAnemiaComputer Science - Artificial Intelligencemedicine.medical_treatmentMedicine (miscellaneous)Machine Learning (stat.ML)Outcome (game theory)Decision Support TechniquesMachine Learning (cs.LG)Renal DialysisArtificial IntelligenceStatistics - Machine LearningmedicineHumansReinforcement learningDosingAgedProtocol (science)Patient SelectionAnemiaHemoglobin AMiddle Agedmedicine.diseaseMarkov ChainsComputer Science - LearningArtificial Intelligence (cs.AI)Chronic DiseaseHematinicsKidney Failure ChronicFemaleHemodialysisMarkov decision processReinforcement PsychologyAlgorithmsmedicine.drug
researchProduct

Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study

2013

Population-based information on the survival of patients with myeloid malignancies is rare mainly because some entities were not recognized as malignant until the publication of the third revision of the International Classification of Diseases for Oncology and World Health Organization classification in 2000. In this study we report the survival of patients with myeloid malignancies, classified by updated criteria, in Europe. We analyzed 58,800 cases incident between 1995 to 2002 in 48 population-based cancer registries from 20 European countries, classified into HAEMACARE myeloid malignancy groupings. The period approach was used to estimate 5-year relative survival in 2000-2002. The rela…

MaleMyeloidMyeloproliferative disorders -- DiagnosisMyelodysplastic–myeloproliferative diseaseshemic and lymphatic diseasesMyelodysplastic Syndromes/embryology/mortalityRegistriesCàncerCancerAged 80 and overMielomeseducation.field_of_studyRelative survivalMyeloid leukemiaArticlesHematologyMiddle AgedEuropemedicine.anatomical_structureMyelodysplastic-Myeloproliferative Diseases/epidemiology/mortalityAplastic anemia -- TreatmentFemaleAdultmedicine.medical_specialtyAdolescentPopulationMyelodysplastic syndromesmyeloid malignancies; survivalmyeloid malignanciesBone marrow -- TumorssurvivalNOEurope/epidemiologyYoung AdultInternal medicinemedicineHumanseducationSurvival analysisddc:613AgedMedul·la òssia -- TumorsEssential thrombocythemiabusiness.industryMyelodysplastic syndromesmedicine.diseaseThrombocytopeniaMyelodysplastic-Myeloproliferative DiseasesSurvival AnalysisMyelodysplastic SyndromesImmunologyMyélomesbusiness
researchProduct

Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, second…

2002

Abstract Imatinib mesylate, a tyrosine kinase inhibitor targeting bcr-abl, platelet-derived growth factor receptor (PDGF-R), and c-Kit, effectively induces hematologic and cytogenetic remissions in bcr-abl+ chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) with only mild to moderate side effects. Here, we describe the successful treatment of a 64-year-old man with c-Kit+ secondary acute myeloid leukemia (AML) refractory to standard chemotherapy. Upon 2 weeks of imatinib mesylate administration, the patient achieved a complete hematologic remission in peripheral blood. In addition, complete clearance of leukemic blasts in bone marrow and a significant cytogenetic response…

MaleMyeloidmedicine.drug_classmedicine.medical_treatmentImmunologyAntineoplastic AgentsBiochemistryTyrosine-kinase inhibitorPiperazinesBone MarrowRecurrencehemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsmedicineSecondary Acute Myeloid LeukemiaHumansReceptors Platelet-Derived Growth FactorEnzyme InhibitorsneoplasmsSalvage TherapyChemotherapyAnemia Refractory with Excess of Blastsbusiness.industryAnemia RefractoryDaunorubicinRemission InductionCytarabineMyeloid leukemiaCell BiologyHematologyExonsMiddle Agedmedicine.diseaseNeoplasm ProteinsLeukemiaLeukemia Myeloid AcuteProto-Oncogene Proteins c-kitmedicine.anatomical_structureImatinib mesylatePyrimidinesDrug Resistance NeoplasmImmunologyBenzamidesCancer researchDisease ProgressionImatinib MesylateNeoplastic Stem CellsBone marrowbusinessBlood
researchProduct

Cancer in Children With Fanconi Anemia and Ataxia-Telangiectasia—A Nationwide Register-Based Cohort Study in Germany

2021

PURPOSE Fanconi anemia (FA) and ataxia-telangiectasia (AT) are rare inherited syndromes characterized by abnormal DNA damage response and caused by pathogenic variants in key DNA repair proteins that are also relevant in the pathogenesis of breast cancer and other cancer types. The risk of cancer in children with these diseases is poorly understood and has never been assessed in a population-based cohort before. METHODS We identified 421 patients with FA and 160 patients with AT diagnosed between 1973 and 2020 through German DNA repair disorder reference laboratories. We linked patients' laboratory data with childhood cancer data from the German Childhood Cancer Registry. RESULTS Among 421 …

MaleOncologyRegister basedCancer Researchmedicine.medical_specialtyTime FactorsAdolescentDNA damageAnemiaDNA repairRisk AssessmentAtaxia TelangiectasiaRisk FactorsFanconi anemiaGermanyNeoplasmsInternal medicinemedicineHumansRegistriesChildbusiness.industryIncidenceAge FactorsInfantCancerPrognosismedicine.diseaseFanconi AnemiaOncologyChild PreschoolAtaxia-telangiectasiaFemalebusinessCohort studyJournal of Clinical Oncology
researchProduct

Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report

2012

Abstract Background Primary myelofibrosis is a myeloproliferative disorder characterized by bone marrow fibrosis, abnormal cytokine expression, splenomegaly and anemia. The activation of JAK2 and the increased levels of circulating proinflammatory cytokines seem to play an important role in the pathogenesis of myelofibrosis. Novel therapeutic agents targeting JAKs have been developed for the treatment of myeloproliferative disorders. Ruxolitinib (INCB018424) is the most recent among them. Case presentation To our knowledge, there is no evidence from clinical trials of an increased risk of tuberculosis during treatment with JAK inhibitors. Here we describe the first case of tuberculosis in a…

MaleOncologymedicine.medical_specialtyRuxolitinibTuberculosisSettore MED/17 - Malattie InfettiveAnemiaAntitubercular AgentsMyelofibrosislcsh:MedicineCase ReportGeneral Biochemistry Genetics and Molecular BiologyProinflammatory cytokineMyeloproliferative DisordersInternal medicineNitrilesmedicineHumansTuberculosisMyelofibrosislcsh:Science (General)lcsh:QH301-705.5Medicine(all)Janus kinase 2biologyLatent tuberculosisBiochemistry Genetics and Molecular Biology(all)business.industryTuberculosis Myelofibrosis Ruxolitiniblcsh:RGeneral MedicineJanus Kinase 2medicine.diseasePyrimidinesRuxolitiniblcsh:Biology (General)Primary MyelofibrosisImmunologybiology.proteinPyrazolesbusinessmedicine.druglcsh:Q1-390BMC Research Notes
researchProduct

A case of sjögren's syndrome with severe anemia due to myelitis

1986

An unusual case of Sjögren's syndrome presenting with severe anemia as the predominant clinical feature is described. Histological examination of a bone marrow biopsy specimen demonstrated that the patient's anemia was caused by myelitis and vasculitis of the small intraosseous vessels. Our report might stimulate a more thorough investigation of bone marrow in patients with connective tissue diseases and anemia.

MalePathologymedicine.medical_specialtyAnemiaConnective tissueMyelitisSevere anemiaBone Marrowhemic and lymphatic diseasesDrug DiscoveryBiopsymedicineHumansGenetics (clinical)medicine.diagnostic_testbusiness.industryAnemiaOsteomyelitisArteriesGeneral MedicineMiddle AgedHematopoietic Stem Cellsmedicine.diseasePolyarteritis NodosaSjogren's Syndromemedicine.anatomical_structureMolecular MedicineBone marrowSjogren sbusinessVasculitisKlinische Wochenschrift
researchProduct